HIGHLIGHTS
- who: Susanne Schiffmann and collaborators from the Fraunhofer Institute for Translational Medicine and Pharmacology (ITMP), Theodor-Stern-Kai, Frankfurt am Main, Germany Pharmazentrum Frankfurt/ZAFES, Department of Clinical Pharmacology, Goethe-University Hospital have published the research: In Vitro Safety, Off-Target and Bioavailability Profile of the Antiviral Compound Silvestrol, in the Journal: Pharmaceuticals 2022, 1086 of 12/07/2022
- what: The main therapeutic indicator from the studies discussed is that bioavailability of silvestrol is rather low, indicating that oral application should be avoided and local administration, for example, via inhalation, should be clearly preferred.
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.